AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
AGIO(NASDAQ:AGIO) LOS ANGELES--(BUSINESS WIRE)---- $AGIO--AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
AGIO(NASDAQ:AGIO) Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025
Agios, Avanmzanite Sign Agreement For Pan-European Partnership For PYRUKYND Launch
AGIOAgios Pharma: New Data On PK Activators, Mitapivat And Tebapivat, To Be Featured In Oral And Poster Presentations During EHA Congress 2025
AGIOScotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Lowers Price Target to $71
AGIOAgios Pharmaceuticals Q1 EPS $(1.55) Beats $(1.80) Estimate, Sales $8.73M Miss $9.64M Estimate
AGIOAn Overview of Agios Pharmaceuticals's Earnings
AGIOHC Wainwright & Co. Reiterates Buy on Agios Pharmaceuticals, Maintains $58 Price Target
AGIOAgios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
AGIOAgios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.
Agios Pharmaceuticals Q4 Sales $10.70M Beat $9.33M Estimate, Net Loss Of $96.5M Vs. $95.9M YoY, Cash Balance Of $1.5B
AGIOAgios Pharmaceuticals FY 2024 GAAP EPS $11.64 Beats $11.46 Estimate, Sales $36.50M Beat $35.13M Estimate
AGIOAgios Says ACTIVATE-Kids Phase 3 Study Of Mitapivat Met Primary Endpoint
AGIOAgios Reveals Anticipated Key 2025 Milestones And Value-driving Catalysts Through 2026
AGIOAgios Pharmaceuticals Announced It Will Present New Data And Results From Its Phase 3 Study On AG-946 At The 66th American Society Of Hematology Annual Meeting In San Diego, California From December 7-10, 2024
AGIODeep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
AGIORBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
AGIOScotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $53
AGIOAgios Expects Cash And Equivalents, Together With Anticipated Product Revenue And Interest Income, To Provide Financial Independence To Prepare For Potential PYRUKYND Launches, Advance Existing Programs, And Expand Pipeline
AGIOAgios Pharmaceuticals Q3 Sales $8.96M Miss $9.46M Estimate
AGIOAttention Biotech Investors - Stocks To Watch From RBC Global Healthcare Conference
AGIORBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.
